Global Lymphedema Treatment Market - Industry Trends and Forecast to 2029
- Published Date: 2022-11-21
- Report ID: 144452
- Pages: 200
-
Format:
Short Description:
Global Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines , Vietnam, and Rest of Asia-Pacific, Brazil, Argentina , Peru, and Rest of South America, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
Lymphedema refers to swelling that generally occurs in upper and lower extremities. Sometimes both arms and both legs swell. Lymphedema is most commonly caused by the removal of or damage to lymph nodes as a part of cancer treatment. It results from a blockage in lymphatic system, which is part of immune system. Stems from a damaged lymphatic system, can lead to infections, disfigurement, debilitating pain and disability. There is no cure for lymphedema.
Lymphedema treatment involves multiple therapies instead of standard treatment, since the patients are dissatisfied or dont get cured with the conventional treatment of lymphedema. They approach the alternative treatment which offers more control over health care decisions, and the alternatives are found to be more compatible with the patients health system.
Lymphedema can occur after any cancer or its treatment that affects lymph node drainage. It has been reported to occur within days and up to 30 years after treatment for breast cancer. The initial stage lymphedema treatments are therapies, surgeries and lymphovenous transplant among others. But there is no permanent cure for lymphedema.
Market Segmentation:
Global lymphedema treatment market is categorized into seven notable segments which are by treatment type, type, affected area, age group, route of administration, end user, and distribution channel.
On the basis of treatment type, global lymphedema treatment market is segmented in compression therapy, surgery, drug therapy, laser therapy and others
On the basis of type, global lymphedema treatment market is segmented in primary lymphedema and secondary lymphedema
On the basis of affected area, global lymphedema treatment market is segmented genital, lower extremity and upper extremity
On the basis of age group, the global lymphedema treatment market is segmented into adult and geriatric
On the basis of route of administration, global lymphedema treatment market is segmented in oral, injectable and others
On the basis of end user, global lymphedema treatment market is segmented in hospitals, ambulatory surgical centres, speciality clinics and others
On the basis of distribution channel, global lymphedema treatment market is segmented in direct tender, pharmacy stores and others
Market Players:
The key market players for the global lymphedema treatment market are listed below:
BIOCOMPRESSION SYSTEMS
Lohmann & Rauscher GmbH & Co. KG
ThermoTek
Cardinal Health
Smith+Nephew
Avet Pharmaceuticals Inc.
KOYA MEDICAL
SIGVARIS GROUP
AIROS Medical, Inc.
Tactile Medical
medi GmbH & Co. KG
PAUL HARTMANN AG
Convatec Inc.
3M
Juzo
Huntleigh Healthcare Limited
HERANTIS PHARMA Plc
Lohmann & Rauscher GmbH & Co. KG
Sanyleg Srl a socio unico
Essity (BSN medical GmbH)
Mego Afek ltd
TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF GLOBAL LYMPHEDEMA TREATMENT MARKET 44
1.4 LIMITATIONS 46
1.5 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 CURRENCY AND PRICING 51
2.5 DBMR TRIPOD DATA VALIDATION MODEL 52
2.6 MULTIVARIATE MODELLING 55
2.7 PRODUCT TYPE LIFELINE CURVE 56
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.9 DBMR MARKET POSITION GRID 58
2.10 MARKET APPLICATION COVERAGE GRID 59
2.11 VENDOR SHARE ANALYSIS 60
2.12 SECONDARY SOURCES 61
2.13 ASSUMPTIONS 61
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 66
4.1 PESTEL'S ANALYSIS 69
4.2 PORTER'S MODEL 70
5 PIPELINE ANALYSIS FOR GLOBAL LYMPHEDEMA TREATMENT MARKET 71
6 EPIDEMIOLOGY 72
7 REGULATORY GUIDELINES FOR GLOBAL LYMPHEDEMA TREATMENT MARKET 73
7.1 U.S. 73
7.2 EUROPE 74
7.3 INDIA 74
7.4 MEXICO 75
7.5 CANADA 75
8 MARKET OVERVIEW 77
8.1 DRIVERS 79
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY 79
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 79
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 80
8.1.4 MULTIPLE THERAPIES 80
8.2 RESTRAINTS 81
8.2.1 HIGH COST OF TREATMENT 81
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 82
8.3 OPPORTUNITIES 82
8.3.1 DRUG APPROVALS 82
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 83
8.4 CHALLENGES 83
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 83
8.4.2 DIFFICULT REIMBURSEMENT 84
9 IMPACT OF COVID-19 ON THE GLOBAL LYMPHEDEMA TREATMENT MARKET 85
9.1 IMPACT ON PRICE 85
9.2 IMPACT ON DEMAND 85
9.3 IMPACT ON SUPPLY CHAIN 86
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS 86
9.5 CONCLUSION 86
10 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 88
10.1 OVERVIEW 89
10.2 COMPRESSION THERAPY 92
10.2.1 BY PRODUCT 92
10.2.1.1 COMPRESSION PUMPS 92
10.2.1.2 COMPRESSION GARMENTS 92
10.2.1.2.1 COMPRESSION STOCKINGS 93
10.2.1.2.2 COMPRESSION SLEEVES 93
10.2.1.2.3 OTHERS 93
10.2.1.3 COMPRESSION BANDAGES & WRAPS 93
10.2.1.4 OTHERS 93
10.2.2 BY TECHNIQUE 94
10.2.2.1 STATIC COMPRESSION THERAPY 94
10.2.2.2 DYNAMIC COMPRESSION THERAPY 94
10.3 SURGERY 94
10.3.1 LYMPHOVENOUS TRANSPLANT 95
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS 95
10.3.3 LIPOSUCTION 95
10.3.4 OTHERS 95
10.4 DRUG THERAPY 95
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 96
10.4.2 RETINOIDS 96
10.4.3 ANTIBIOTICS 96
10.4.4 OTHERS 96
10.5 LASER THERAPY 97
10.6 OTHERS 98
11 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TYPE 99
11.1 OVERVIEW 100
11.2 SECONDARY LYMPHEDEMA 103
11.3 PRIMARY LYMPHEDEMA 103
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 104
11.3.2 CONGENITAL LYMPHEDEMA 104
11.3.3 LYMPHEDEMA TARDA 104
12 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 105
12.1 OVERVIEW 106
12.2 LOWER EXTREMITY 109
12.3 UPPER EXTREMITY 109
12.4 GENITALIA 110
13 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 111
13.1 OVERVIEW 112
13.2 ADULT 115
13.3 GERIATRIC 115
13.4 PEDIATRIC 116
14 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 117
14.1 OVERVIEW 118
14.2 ORAL 121
14.3 INJECTABLE 121
14.4 TOPICAL 122
15 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY END USER 123
15.1 OVERVIEW 124
15.2 HOSPITAL 127
15.3 SPECIALTY CLINICS 127
15.4 AMBULATORY SURGICAL CENTERS 128
15.5 OTHERS 128
16 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 129
16.1 OVERVIEW 130
16.2 PHARMACY STORES 133
16.3 DIRECT TENDER 133
16.4 OTHERS 134
17 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY REGION 135
17.1 OVERVIEW 136
17.2 NORTH AMERICA 142
17.2.1 U.S. 150
17.2.2 CANADA 153
17.2.3 MEXICO 156
17.3 EUROPE 159
17.3.1 GERMANY 167
17.3.2 FRANCE 171
17.3.3 UNITED KINGDOM 175
17.3.4 ITALY 179
17.3.5 RUSSIA 183
17.3.6 SPAIN 187
17.3.7 TURKEY 191
17.3.8 NETHERLANDS 195
17.3.9 SWITZERLAND 199
17.3.10 BELGIUM 203
17.3.11 POLAND 207
17.3.12 AUSTRIA 211
17.3.13 HUNGARY 215
17.3.14 NORWAY 219
17.3.15 IRELAND 223
17.3.16 LITHUANIA 227
17.3.17 REST OF EUROPE 231
17.4 ASIA-PACIFIC 232
17.4.1 CHINA 241
17.4.2 JAPAN 245
17.4.3 INDIA 249
17.4.4 SOUTH KOREA 252
17.4.5 AUSTRALIA 256
17.4.6 INDONESIA 259
17.4.7 SINGAPORE 262
17.4.8 PHILIPPINES 265
17.4.9 THAILAND 269
17.4.10 MALAYSIA 272
17.4.11 VIETNAM 275
17.4.12 REST OF ASIA-PACIFIC 278
17.5 SOUTH AMERICA 279
17.5.1 BRAZIL 287
17.5.2 ARGENTINA 291
17.5.3 PERU 294
17.5.4 REST OF SOUTH AMERICA 298
17.6 MIDDLE EAST AND AFRICA 299
17.6.1 SOUTH AFRICA 307
17.6.2 SAUDI ARABIA 311
17.6.3 EGYPT 315
17.6.4 U.A.E 319
17.6.5 ISRAEL 323
17.6.6 KUWAIT 327
17.6.7 REST OF MIDDLE EAST AND AFRICA 331
18 GLOBAL LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE 332
18.1 COMPANY SHARE ANALYSIS: GLOBAL 332
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 333
18.3 COMPANY SHARE ANALYSIS: EUROPE 334
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 335
19 SWOT ANALYIS 336
20 COMPANY PROFILE 337
20.1 TACTILE MEDICAL 337
20.1.1 COMPANY SNAPSHOT 337
20.1.2 REVENUE ANALYSIS 337
20.1.3 COMPANY SHARE ANALYSIS 338
20.1.4 PRODUCT PORTFOLIO 338
20.1.5 RECENT DEVELOPMENT 338
20.1.6 CLINICAL TRIAL: 338
20.2 ESSITY (BSN MEDICAL GMBH) 339
20.2.1 COMPANY SNAPSHOT 339
20.2.2 COMPANY SHARE ANALYSIS 339
20.2.3 PRODUCT PORTFOLIO 339
20.2.4 RECENT DEVELOPMENT 340
20.3 3M 341
20.3.1 COMPANY SNAPSHOT 341
20.3.2 REVENUE ANALYSIS 341
20.3.3 COMPANY SHARE ANALYSIS 342
20.3.4 PRODUCT PORTFOLIO 342
20.3.5 RECENT DEVELOPMENTS 342
20.3.6 NEW BUSINESS SEGMENT 342
20.3.7 ACQUISITION 343
20.4 CARDINAL HEALTH 344
20.4.1 COMPANY SNAPSHOT 344
20.4.2 REVENUE ANALYSIS 344
20.4.3 COMPANY SHARE ANALYSIS 345
20.4.4 PRODUCT PORTFOLIO 345
20.4.5 RECENT DEVELOPMENT 345
20.5 LOHMANN & RAUSCHER GMBH & CO. KG 346
20.5.1 COMPANY SNAPSHOT 346
20.5.2 COMPANY SHARE ANALYSIS 346
20.5.3 PRODUCT PORTFOLIO 347
20.5.4 RECENT DEVELOPMENT 347
20.6 AIROS MEDICAL, INC. 348
20.6.1 COMPANY SNAPSHOT 348
20.6.2 PRODUCT PORTFOLIO 348
20.6.3 RECENT DEVELOPMENT 348
20.6.4 PRODUCT LAUNCH: 348
20.7 AVET PHARMACEUTICALS INC. 349
20.7.1 COMPANY SNAPSHOT 349
20.7.2 PRODUCT PORTFOLIO 349
20.7.3 RECENT DEVELOPMENT 349
20.8 BIOCOMPRESSION SYSTEMS 350
20.8.1 COMPANY SNAPSHOT 350
20.8.2 PRODUCT PORTFOLIO 350
20.8.3 RECENT DEVELOPMENT 351
20.8.4 AGREEMENT 351
20.9 CONVATEC INC. 352
20.9.1 COMPANY SNAPSHOT 352
20.9.2 PRODUCT PORTFOLIO 352
20.9.3 RECENT DEVELOPMENT 352
20.10 HERANTIS PHARMA PLC 353
20.10.1 COMPANY SNAPSHOT 353
20.10.2 RECENT DEVELOPMENT 353
20.11 HUNTLEIGH HEALTHCARE LIMITED 354
20.11.1 COMPANY SNAPSHOT 354
20.11.2 PRODUCT PORTFOLIO 354
20.11.3 RECENT DEVELOPMENT 354
20.12 JUZO 355
20.12.1 COMPANY SNAPSHOT 355
20.12.2 PRODUCT PORTFOLIO 355
20.12.3 RECENT DEVELOPMENT 355
20.13 KOYA MEDICAL 356
20.13.1 COMPANY SNAPSHOT 356
20.13.2 PRODUCT PORTFOLIO 356
20.13.3 RECENT DEVELOPMENT 356
20.13.4 APPROVAL 356
20.14 MEDI GMBH & CO. KG 357
20.14.1 COMPANY SNAPSHOT 357
20.14.2 PRODUCT PORTFOLIO 357
20.14.3 RECENT DEVELOPMENT 357
20.15 MEGO AFEK LTD 358
20.15.1 COMPANY SNAPSHOT 358
20.15.2 PRODUCT PORTFOLIO 358
20.15.3 RECENT DEVELOPMENT 359
20.15.4 APPLICATION LAUNCH: 359
20.16 PAUL HARTMANN AG 360
20.16.1 COMPANY SNAPSHOT 360
20.16.2 REVENUE ANALYSIS 360
20.16.3 PRODUCT PORTFOLIO 361
20.16.4 RECENT DEVELOPMENTS 361
20.17 SANYLEG SRL A SOCIO UNICO 362
20.17.1 COMPANY SNAPSHOT 362
20.17.2 PRODUCT PORTFOLIO 362
20.17.3 RECENT DEVELOPMENT 362
20.18 SIGVARIS GROUP 363
20.18.1 COMPANY SNAPSHOT 363
20.18.2 PRODUCT PORTFOLIO 363
20.18.3 RECENT DEVELOPMENTS 364
20.18.4 PRODUCT LAUNCHES: 364
20.19 SMITH +NEPHEW 365
20.19.1 COMPANY SNAPSHOT 365
20.19.2 REVENUE ANALYSIS 365
20.19.3 PRODUCT PORTFOLIO 366
20.19.4 RECENT DEVELOPMENT 366
20.20 THERMOTEK 367
20.20.1 COMPANY SNAPSHOT 367
20.20.2 PRODUCT PORTFOLIO 367
20.20.3 RECENT DEVELOPMENT 367
21 QUESTIONNAIRE 368
22 RELATED REPORTS 372
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
